The innovative XL optic of the ASPIRA-aXA combines the advantages of a 7.0 mm optic with the stability of the innovative cut-out haptic design, conveniently provided in the preloaded SAFELOADER® implantation system.
| Type | Monofocal 1-piece posterior chamber lens, foldable |
| Optic diameter | 7.0 mm |
| Total diameter | 11.0 mm |
| Material | Glistening-free, hydrophilic acrylic, UV blocker |
| Optic features | Aspherical anterior surface, aberration-free, 360° LEC barrier, HD optic |
| Haptic design | Cut-out haptics |
| Estimated A-constant (optical biometry) | 118.3 |
| XL diopter range | 10.0 to 30.0 D in 0.5 D steps Preloaded in SAFELOADER® |
ASPIRA-aXA provides a tailor-made solution for a diverse range of needs. Possible applications range from standard cataract and refractive surgeries to combined retinal surgery interventions.
Due to its XL 7.0 mm optic, this posterior chamber lens supplies the best conditions for long-term pseudophakic reliability for the patient. The extended fundus view, which is enabled by the possibility of a rhexis diameter of up to 6.5 mm, represents an enormous contribution to preventive patient management and early detection of ocular diseases.
Risk factors such as diabetes or hypertension are continuously increasing in our population.
Especially for this group within the cataract patients, the ASPIRA-aXA lays the foundations for long-term pseudophakic reliability.
Intraoperative image (using Verion) with implanted ASPIRA-aXA. Edge of the XL optic (black). Rhexis, diameter 6.0 mm (blue).
From a vitreoretinal point of view, both the surgeon and the postoperative doctor benefit from the extended fundus view. The assessment of the posterior segment of the eye and the implementation of therapeutic measures for peripheral retinal diseases can occur more conveniently.
ASPIRA-aXA offers patients with an increased risk of ocular diseases an advantage for long-term, successful pseudophakic treatment.
The ASPIRA-aXA is also an ideal treatment option for patients with large pupils. In these patients, the mesopic pupil width often exceeds the diameter of the IOL optic. Off-axis rays are scattered on the edge of the optic or pass the IOL and strike the retina as stray light. The result can be an increased incidence of dysphotopsia. With a conventional 6.0 mm optic, the patient could be affected by edge effects or other light phenomena.
The ASPIRA-aXA with its XL optic is an ideal treatment option for large pupils.
Simulated beam guidance (temporal), based on a simulation using Zemax, OpticStudio 16.5 with a 6 mm optic and a 7 mm optic; pupil size 4 mm each.
Combining the benefits of C-loop haptics and conventional plate haptics for added stabilization:
Schematic drawing:
When force is applied, the cut-out haptics prove to be stable elements for positioning the IOL.
HumanOptics AG (2017). Invitro-Simulation, Data on file.
The ASPIRA-aXA is provided precisely and reliably by the unique autoloading SAFELOADER® system:
Optional combination with the Medicel-Accuject™ injector in sizes 2.0 and 2.2;
Recommended application: in-the-bag
Prof. G. Duncker, Halle
“The new ASPIRA-aXA combines an excellent, stable optic with easy in-the-bag implantation through a 2.4 mm incision. The patient response has been overwhelmingly positive.”
Personal Statement, 2018
Prof. W. Sekundo, Marburg
“The large ASPIRA-aXA optic has proven itself in phaco-vitrectomies because it allows an edge-free view into the outer retinal periphery.”
Personal Statement, 2018
Dr. Becker/Piskula, Oranienburg
“The ASPIRA-aXA with its enlarged XL optic represents a promising approach to minimize dysphotopsia.”
Piskula, M. Becker, E. (2018). Reduzierte pseudophake Dysphotopsien durch vergrößerte IOL-Optik. Presentation DGII 2018.
Takamura, MD, PhD
“The creation of a larger capsulorhexis with implantation of a 7.0 mm optic IOL contributed to a larger anterior capsule opening after cataract surgery in patients with DM [diabetes mellitus].”
Takamura, Y., et al. Large capsulorhexis with implantation of a 7,0 mm optic lens during cataract surgery in patients with diabetes mellitus. J Catract Refract Surg 2014; 40(11):1850-1856.
The ASPIRA-aXA has proven its excellent clinical properties.*
* HumanOptics AG (2018). Interim Study Analysis, Data on file.
Excellent visual performance
Patients treated with ASPIRA-aXA showed good uncorrected monocular distance visual acuity (UDVA) one month and three months postoperatively (n = 58). Corrected distance visual acuity (CDVA) was 0.00 logMAR (median) at both follow-ups with 93% of eyes achieving 0.10 logMAR or better.
Excellent contrast sensitivity
After implantation with ASPIRA-aXA, patients achieved better contrast vision under both photopic and mesopic conditions, compared to non-operated persons of the same age group.
Results
The ASPIRA-aXA achieves very good clinical results in terms of visual performance, contrast sensitivity and patient satisfaction. The IOL demonstrates stable centration during the study. Nd:YAG capsulotomy was unnecessary in all cases. The ASPIRA-aXA is a safe and effective intraocular lens for the treatment of cataract patients.
100% patient satisfaction
A patient survey indicated that all patients were either satisfied or very satisfied with the ASPIRA-aXA. Furthermore, 3 months postoperatively, 100% of the patients stated that they rarely or never noticed photic phenomena.
Separate components for maximum safety
The contactless preloaded implantation system offers a maximum of safety due to separation of the components. Both the IOL and the injector undergo separate sterilization processes. The isolated storage of the IOL ensures that it only comes into contact with the coating additives of the cartridge immediately prior to the surgery.
Easy to use: maximum flexibility
Another strength of the SAFELOADER® lies in its uncomplicated usage. The two-component autoloading system offers individual flexibility in the OR: combine the premium IOL of your choice with the desired incision size of the respective injector for minimally invasive implants (MICS).
This post is also available in: German
Our experts support you with your questions at any time.
News
From September 21. to September 25. 2018 the 36. congress of the European Society of Cataract and Refractive Surgeons took place in Vienna. HumanOptics AG successfully launched the new intraocular lens ASPIRA-aXA for the European market.
With ist 7.0 mm XL optic, the ASPIRA-aXA aroused great interest. The preloaded ASPIRA-aXA provides a convenient implantation of an IOL with XL optic by maintenance of the routine in the OR. For patients with increased risk of ocular diseases the ASPIRA-aXA lays the foundations for a long-term pseudophakic reliability. The posterior chamber lens with its XL optic is also an ideal treatment option for patients with large pupils.
One of HumanOptics‘ highlights was the forum Meet the Expert. Prof. Matthias Bolz (Kepler Universitätsklinikum Linz, Austria) presented results with the ASPIRA-aXA, showed areas of application and informed about relevant factors for a successful implantation.
Another popular topic was the CUSTOMFLEX® ARTIFICIALIRIS. The iris prothesis has received FDA approval recently and is at present the only product of this kind that is approved for the highly attractive U.S. market and addresses this currently unmet medical need in that market.
The bright, welcoming booth was used for conversations and consultations about the product portfolio of HumanOptics efficiently.
